prednisone has been researched along with abt-199 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 8 (72.73) | 2.80 |
| Authors | Studies |
|---|---|
| Cartron, G; Casulo, C; Chamuleau, MED; Goy, A; Herter, S; Ingalla, E; Klein, C; Kornacker, M; Le Gouill, S; Lugtenburg, PJ; Mason, KD; Mobasher, M; Morschhauser, F; Petrich, AM; Salles, G; Samineni, D; Sampath, D; Sehn, LH; Sinha, A; Szafer-Glusman, E; Tam, CS; Tilly, H; Zelenetz, AD | 1 |
| Arias-Martínez, A; Carriles, C; Menárguez-Blanc, R; Ordóñez-Fernández, L; Rosado-María, MC | 1 |
| Ammatuna, E; de Jong, MRW; Langendonk, M; Nijland, M; Reitsma, B; van den Berg, A; van Meerten, T; Visser, L | 1 |
| Bazeos, A; Clark, E; de Vos, S; Feugier, P; Flinn, IW; Gasiorowski, R; Greil, R; Humphrey, K; Illés, Á; Jiang, Y; Johnson, NA; Kim, SY; Larouche, JF; Lugtenburg, PJ; Mir, F; Morschhauser, F; Patti, C; Punnoose, E; Salles, GA; Samineni, D; Sinha, A; Spielewoy, N; Trněný, M; Zelenetz, AD | 1 |
| Chamuleau, MED | 1 |
| Hang, SJ; Jin, J; Qian, JJ; Shen, YJ; Zhang, Y; Zhu, HH | 1 |
| Brown, JR; Davids, MS; Fisher, DC; Ihuoma, U; Jacobson, CA; Lehmberg, TZ; Montegaard, J; Parry, EM; Pazienza, S; Renner, SK; Rogers, KA; Thompson, PA; Tyekucheva, S; Wang, Z; Wu, CJ | 1 |
| Bazeos, A; Ding, H; Gibiansky, L; Huang, W; Humphrey, K; Li, C; Miles, D; Rajwanshi, R; Salem, AH; Samineni, D; Sinha, A; Zhang, R | 1 |
| Cahill, KE; Smith, SM | 1 |
| Cho, H; Choi, HS; Choi, YS; Han, JH; Hwang, S; Jeong, S; Jeong, SH; Kim, DE; Kim, H; Kim, SJ; Pak, HK; Park, CS; Park, JS; Roh, J; Yoon, DH | 1 |
1 review(s) available for prednisone and abt-199
| Article | Year |
|---|---|
Follicular Lymphoma: a Focus on Current and Emerging Therapies
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Genetic Testing; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Prednisone; Pyridones; Rituximab; Sulfonamides; Vincristine | 2022 |
4 trial(s) available for prednisone and abt-199
| Article | Year |
|---|---|
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Rituximab; Sulfonamides; Vincristine | 2019 |
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Fatigue; Female; Gastrointestinal Diseases; Genes, bcl-2; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Proteins; Prednisone; Proto-Oncogene Proteins c-bcl-2; Rituximab; Sulfonamides; Vincristine; Young Adult | 2021 |
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Prednisone; Progression-Free Survival; Sulfonamides; Vincristine | 2022 |
Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Sulfonamides; Treatment Outcome; Vincristine | 2022 |
6 other study(ies) available for prednisone and abt-199
| Article | Year |
|---|---|
Autoimmune hemolytic anemia, adverse event to venetoclax.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Salvage Therapy; Sulfonamides; Vincristine | 2019 |
Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Myeloid Cell Leukemia Sequence 1 Protein; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rituximab; Signal Transduction; Sulfonamides; Thiophenes; Treatment Outcome; Vincristine | 2019 |
Venetoclax Boosts Benefits of R-EPOCH in Aggressive B-Cell Lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Prednisone; Sulfonamides; Vincristine | 2020 |
Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Prednisone; Sulfonamides; Vincristine | 2021 |
The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Sulfonamides | 2022 |
The comprehensive expression of BCL2 family genes determines the prognosis of diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Vincristine | 2023 |